Clinical trial results for
previously treated
advanced esophageal
squamous cell cancer
For people with previously treated advanced
esophageal squamous cell cancer
Actor portrayals.
An FDA-approved immunotherapy that helped people live longer compared to chemotherapy
About the clinical trial
In a clinical trial of 419 people with advanced esophageal squamous cell cancer that had been previously treated with fluoropyrimidine- and platinum-based chemotherapy, 210 people were given OPDIVO and 209 people were given either docetaxel or paclitaxel chemotherapy.
People given OPDIVO lived longer compared to chemotherapy
OPDIVO
Half the people were alive
Chemotherapy
Half the people were alive
In the clinical trial, people given OPDIVO had a 23% lower risk of dying than those given docetaxel or paclitaxel chemotherapy.
There was no significant difference between the two treatments in the percentage of patients who responded to treatment and in the length of time that patients lived without their tumors worsening.
OPDIVO will not work for everyone. Individual results may vary.
OPDIVO Qvantig may be a faster* way to receive treatment.
It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig cannot be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.
Getting treatment
See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)
For adults with previously treated advanced esophageal squamous cell cancer
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) if your esophageal cancer is a type called squamous cell carcinoma, and cannot be removed with surgery, and has come back or spread to other parts of the body after you have received chemotherapy that contains fluoropyrimidine and platinum.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is a prescription medicine used alone to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) if your esophageal cancer is a type called squamous cell carcinoma, and cannot be removed with surgery, and has come back or spread after you have received chemotherapy that contains fluoropyrimidine and platinum.
It is not known if OPDIVO Qvantig is safe and effective in children.